In real life, the implementation rates will never reach 100% due to the contra-indication for HER2-targeted therapy plus chemotherapy, such as comorbidity (renal dysfunction, cardiovascular disease), performance status > 2, and patient preferences. Here, ERBB2 is linked to Abnormal renal physiology.